A Texas A&M-led team regrew bone, joint tissue, tendons and ligaments in amputated adult mouse digits using a sequenced FGF2-then-BMP2 treatment at a site that normally does not regenerate.
Four days after amputation, FGF2 induced a blastema-like cell mass; BMP2 applied 5 days later drove those wound-site cells to differentiate into new skeletal and connective tissues.
Lineage tracing showed the rebuilding cells were local fibroblasts that would normally form scar tissue, not transplanted stem cells, reframing mammalian regeneration as a suppressed capability rather than a lost one.
Micro-CT and histology confirmed parallel rebuilding of distal bone and a joint complex, though the structures were imperfect and not yet functional replicas.
Published April 17 in Nature Communications, the mouse-only proof of concept remains far from human treatment because timing, scaling and BMP2 safety risks still need to be resolved.
If our bodies have the latent ability to regrow limbs, why did evolution choose scarring instead?
Could this science soon allow our bodies to self-repair organs, ending transplant waiting lists?
Could unlocking our dormant regenerative powers accidentally unleash uncontrolled growths like cancer?
Texas A&M Scientists Enable Mouse Limb Regrowth in 2026, Challenging Limits of Mammalian Regeneration
Overview
In June 2026, the Texas A&M team made a major breakthrough by successfully regrowing complex limb structures in mice. This discovery challenges the old belief that mammals cannot regenerate limbs, showing instead that this ability is a suppressed potential that can be reactivated. Using a carefully sequenced two-protein signal—first applying FGF2, then BMP2—to amputated mouse digits, the researchers achieved remarkable anatomical restoration. This turning point in regenerative medicine offers new hope for people who have lost limbs and opens exciting new paths for future therapies.